Back to Watchlist

Evidence memo

TB-500 / thymosin beta-4 claims

Also tracked as: Thymosin beta-4, Tβ4, TB-500

A major identity problem: studied thymosin beta-4 contexts are not the same as broad internet TB-500 recovery claims.

Safety/regulatory watch Investigational Safety watch

Evidence status

Safety/regulatory watch. Evidence level: Safety/regulatory watch.

Claim being evaluated

Whether claims made for TB-500 are actually supported by thymosin beta-4 studies, and whether the product identity is comparable.

Why people care

Recovery and tissue-repair narratives are common online, especially around musculoskeletal use.

Signal so far

There are biologically interesting thymosin beta-4 data in specific wound and eye contexts, but internet TB-500 claims often overgeneralize.

Biggest unknown

Product identity, human outcome evidence for the claimed use, safety, and whether studied formulations map to marketed peptides.

Safety/regulatory boundary

Treat TB-500-style claims as a regulatory and identity watch item, not as a validated recovery tool.

Watch next

Clearer human trials by indication, product characterization, and FDA compounding updates.

Evidence interpretation

The key distinction is not just evidence level; it is whether the named product matches the evidence being cited.

References